IDRA-21 Powder
€ 39,90 – € 298,75Price range: € 39,90 through € 298,75
IDRA-21 Powder is described as a synthetic small-molecule research material associated with 7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide.
The named compound belongs to the benzothiadiazine dioxide family and is discussed in pharmacological literature as a positive allosteric modulator of AMPA-type glutamate receptors.
The supplied source identifies a lyophilized powder presentation intended for controlled analytical and neuroscience-oriented laboratory research.
Its stated scientific context includes compound characterization, receptor-modulation studies, analytical method development, and non-clinical investigation of excitatory neurotransmission.
The supplied molecular formula and approximate molecular weight are arithmetically consistent, but the product’s chemical identity and physical presentation have not been independently verified.
The source reports high purity, commonly at or above 99% where documented, but no batch-specific analytical report accompanied that claim.
The material is not established as a certified reference material or validated quantitative calibration standard.
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
IDRA-21 Powder – AMPA Receptor Research Compound
Product Overview
IDRA-21 Powder is described as a synthetic small-molecule research material associated with 7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide.
The named compound belongs to the benzothiadiazine dioxide family and is discussed in pharmacological literature in connection with AMPA-type glutamate receptor modulation.
The supplied source identifies IDRA-21 as a positive allosteric modulator of AMPA-type receptors.
This pharmacological classification provides a scientific context for studying receptor-associated molecular interactions and excitatory neurotransmission in non-clinical research.
The source describes the product as a high-purity, lyophilized powder intended for controlled laboratory environments.
However, no actual product-specific inspection report, analytical identity certificate, or manufacturing record accompanied the supplied information.
The claimed lyophilized presentation therefore remains a source-provided specification.
The source also refers to batch documentation, identity verification, purity data, and controlled handling.
These statements identify the intended research positioning but do not independently establish product quality or regulatory compliance.
IDRA-21 Powder is not established here as a certified reference material, validated quantitative calibrator, or approved pharmaceutical preparation.
Chemical Identity & Classification
The supplied source identifies IDRA-21 as 7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide.
Its chemical classification places it within the benzothiadiazine dioxide family.
The supplied chemical information includes:
- Common designation: IDRA-21
- Chemical name: 7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide
- Reported CAS Registry Number: 22503-72-6
- Reported molecular formula: C₈H₉ClN₂O₂S
- Approximate molecular weight: 232.7 g/mol
- Chemical classification: Benzothiadiazine dioxide derivative
- Reported presentation: Lyophilized powder
- Intended designation: Research Use Only
The reported molecular formula corresponds to an approximate molecular weight of 232.69 g/mol, consistent with the source’s rounded value.
This arithmetic consistency does not independently verify the actual product identity.
The supplied information does not establish a particular salt form, stereochemical composition, or batch-specific structural confirmation.
The reported CAS number and chemical name should be checked against authoritative chemical-reference information and actual analytical documentation before being treated as independently verified product identifiers.
Researchers may consult PubChem for public chemical-reference information, while ensuring that the selected database entry corresponds to the actual chemical form being examined.
Chemical & Physical Characteristics
The supplied source describes the material as a lyophilized powder.
Lyophilization is a processing technique involving removal of frozen solvent under reduced pressure.
However, the source does not provide a manufacturing record establishing that this particular product underwent lyophilization.
No actual product-specific inspection report, particle-size measurement, melting-point determination, or quantitative solubility profile was provided.
The stated physical presentation therefore remains a source-provided description.
The named compound contains a chlorinated benzothiadiazine dioxide framework.
Its molecular structure includes a heterocyclic system containing nitrogen and sulfur atoms, with the sulfur atom incorporated into a dioxide functional arrangement.
These structural features distinguish IDRA-21 from chemically unrelated receptor-modulation compounds.
However, structural classification alone does not establish experimentally verified solubility, stability, or other physicochemical characteristics of the actual product.
The source does not provide measured melting-point data, degradation profiles, residual-solvent results, or complete physical characterization.
The source recommends cool, dry storage protected from light and moisture.
No validated product-specific stability study or established shelf-life specification accompanied that recommendation.
Purity & Analytical Verification
The supplied source describes IDRA-21 Powder as high purity and refers to analytical verification, commonly at or above 99% by HPLC or LC-MS where documented.
However, no actual batch-specific Certificate of Analysis or laboratory report accompanied the information.
The stated purity threshold therefore remains a supplier-provided claim rather than an independently verified result.
No chromatogram, mass spectrum, NMR spectrum, impurity profile, or independent laboratory certificate was supplied.
Accordingly, no specific purity result can be confirmed for the actual product batch.
The source identifies analytical method development and reference-oriented research as intended laboratory contexts.
Chemical characterization may involve examination of molecular identity, structural features, impurity profiles, and analytical specificity.
However, naming an analytical technique does not establish that the actual product has undergone that test.
The source also describes the material in reference-oriented terms.
That description does not establish certified reference-material status or validated quantitative calibration performance.
No assigned measurement values, uncertainty statements, metrological traceability records, or independently verified analytical specifications were supplied.
Any definitive product-specific analytical claims should be supported by actual batch documentation.
Quality Control & Batch Integrity
The supplied source refers to batch tracking, identity verification, purity data, and Certificate of Analysis-style documentation where applicable.
These statements describe proposed or claimed quality-assurance practices.
No actual certificate, independent testing report, manufacturing audit, laboratory accreditation record, or batch-specific quality-control document accompanied the information.
They therefore remain unverified supplier statements.
For reproducible scientific documentation, relevant records may include verified chemical identifiers, confirmed chemical form where available, batch number, analytical findings, receipt date, and available storage history.
Where a lyophilized presentation is claimed, manufacturing and residual-solvent documentation may also be relevant to verifying that designation.
The supplied information does not establish independently verified purity, chemical form, or batch consistency.
The existence of a Research Use Only designation does not itself demonstrate manufacturing quality or analytical traceability.
Claims of consistent purity, identity, and manufacturing quality should be supported by actual records rather than inferred from general quality-assurance language.
Safety, Handling & Laboratory Precautions
IDRA-21 is a synthetic small-molecule compound associated with pharmacological activity at AMPA-type glutamate receptors.
The supplied source does not provide a complete product-specific toxicological assessment.
Laboratory personnel should consult applicable chemical-safety documentation and institutional procedures before receiving or examining the material.
Relevant precautions include restricted access, appropriate protective equipment, contamination prevention, accidental-exposure procedures, and chemical-waste management.
The powder presentation does not establish safety for human or veterinary exposure.
The material should remain secured against unauthorized access and separated from food, beverages, and non-research environments.
Because the actual chemical form, purity, and physical characteristics have not been independently confirmed, laboratory documentation should distinguish verified characteristics from supplier-provided statements.
Any accidental exposure or contamination incident should be managed according to institutional emergency procedures.
Packaging, Labeling & Storage
The supplied source describes sealed vials or bags, protective packaging, controlled handling, and international shipping arrangements.
No actual packaging specification, container-validation report, or shipment-condition record was provided.
The source recommends storage in a cool, dry environment protected from light and moisture, with containers kept tightly sealed.
No validated product-specific stability data was provided to establish a particular storage temperature or shelf life.
Laboratory inventory records should preserve the product designation, confirmed chemical form where available, any batch identifier, receipt details, and relevant storage observations.
Packaging and environmental requirements should be assessed using available safety documentation, relevant stability evidence, and institutional laboratory procedures.
The source’s general handling recommendations should not be interpreted as evidence of validated long-term stability.
Intended Research Use & Market Positioning
The supplied scientific context places IDRA-21 within analytical and non-clinical neuroscience research involving AMPA-type glutamate receptors and excitatory neurotransmission.
The source identifies the compound as a positive allosteric modulator of AMPA-type receptors.
This classification provides a basis for examining receptor-associated molecular interactions and pharmacological mechanisms in controlled research environments.
However, the source does not provide a product-specific pharmacological assay or independently verified receptor-modulation dataset for the actual powder.
The supplied Raw Lab Chems catalog includes IDRA-21 Powder, corresponding to the listing discussed here.
For broader chemical-catalog context, Raw Lab Chems also lists Fladrafinil Vega Caps and Phenibut HCl Powder.
These listings concern chemically distinct substances with different molecular structures and pharmacological classifications.
They should not be treated as chemically identical or analytically interchangeable with IDRA-21.
The supplied information does not establish equivalent chemical forms, ingredient purity, or analytical characteristics across these listings.
These references provide catalog context rather than evidence of certified reference-material status or product equivalence.
Ordering, Availability & Fulfillment
The supplied source describes protective packaging and international shipping arrangements.
No current inventory record, shipment authorization, carrier documentation, or verified delivery information was supplied.
Consequently, no availability, delivery, customs-clearance, or transportation-compliance guarantee is asserted.
The regulatory treatment of IDRA-21 may depend on the jurisdiction, chemical classification, import requirements, and intended laboratory activity.
Institutional acquisition, possession, transportation, importation, and exportation should be assessed under applicable laws.
Research-only labeling does not independently establish a regulatory exemption.
Legal & Regulatory Disclaimer
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
IDRA-21 is a synthetic benzothiadiazine dioxide derivative discussed in non-clinical pharmacological research.
Its acquisition, possession, transportation, importation, exportation, and laboratory investigation may be subject to applicable chemical, pharmaceutical, customs, and institutional requirements.
The supplied information does not establish universal legal status or regulatory authorization.
Institutions remain responsible for determining the applicable requirements and obtaining any necessary permissions.
No medical approval, consumer-use authorization, or regulatory exemption is implied by this description.
| Quantity (grams) |
2 ,5 ,10 ,25 |
|---|
You must be logged in to post a review.

Reviews
There are no reviews yet.